Lacrimal duct cancer

Summary

Lacrimal duct cancer (MONDO:0001580) is a cancer. A subtype of lacrimal system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lacrimal duct cancer
Mondo ID	MONDO:0001580
DOID	DOID:12756
NCIT	C175319, C3567
SNOMED CT	188274004
UMLS	C0153631
MedGen	57795
Anatomy (UBERON)	UBERON:0001850
Is cancer (heuristic)	yes

Also known as: cancer of lacrimal drainage system · lacrimal drainage system cancer · malignant lacrimal drainage system neoplasm · malignant lacrimal duct neoplasm · malignant lacrimal duct tumor · malignant lacrimal duct tumour · malignant neoplasm of lacrimal drainage system · malignant neoplasm of lacrimal duct · malignant neoplasm of the lacrimal duct · malignant tumor of lacrimal duct · malignant tumor of the lacrimal duct · malignant tumour of lacrimal duct · malignant tumour of the lacrimal duct

Disease family

This is a subtype of lacrimal system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › lacrimal apparatus disorder › lacrimal system cancer › lacrimal duct cancer

Related subtypes (1): lacrimal gland cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.